Skip to content

Board of Directors

The Evox Board of directors is comprised of highly accomplished advisors who each contribute significant expertise in their respective fields. They provide support and guidance to the management team of Evox in achieving its bold vision to positively impact human health by creating novel exosome-based biotherapeutics.

Paul Carter

Non-Executive Chairman

Paul is a widely respected leader and Board member where he has over the last 25 years held a variety of senior commercial leadership roles in the bio-pharmaceutical industry, formally serving as Executive Vice President, Chief Commercial Officer at Gilead Sciences. He currently serves on the Board of several listed and private pharmaceutical companies.

Dr Antonin de Fougerolles

Chief Executive Officer and Director

Tony has over 20 years of biotech R&D experience in building out drug pipelines, and he has played a key role in developing and successfully advancing 3 new drug modalities towards the market and in helping build several multi-billion dollar companies from start-up stage including Ablynx, Moderna and Alnylam.

Dr Per Lundin

Chief Operating Officer and Founder Director

Per has over 10 years of experience in advising, founding and leading biotech companies developing groundbreaking therapies. Prior to co-founding Evox in 2016, he founded and led a cell therapy company, practiced patent law as a European Patent Attorney and worked in business development and consulting.

Amrit Nagpal

Non-Executive Director

Amrit is a Managing Director, Private Investments at Redmile Group, LLC, a healthcare-focused investment firm based in San Francisco and New York.

Martin Andrews

Non-Executive Director

Martin is a respected commercial leader with a strong track record in strategy development and operational delivery most recently as Senior Vice President, Rare Diseases at GlaxoSmithKline, where he oversaw the development and launch of Strimvelis, the world’s first life-saving gene therapy for children. He currently serves on the Board of Freeline Therapeutics.

Sarah Gordon Wild

Non-Executive Director

Sarah has worked on Wall Street for over 15 years and was Managing Director, Management Committee Member and Senior Healthcare Analyst at Lone Pine Capital LLC from 1998 to 2003. She is also currently on the board of Oxford Nanopore.

Professor Matthew Wood

Founder Director

Matthew is Professor of Neuroscience and Deputy Head of the Medical Sciences Division at Oxford University and directs the Laboratory of RNA Biology and Neuromuscular Disease.

Dr Andrew McLean

Non-Executive Director

Andy is the lead life sciences investor at Oxford Sciences Innovation plc overseeing a portfolio of 11 life sciences companies. In this role, he was also involved in seeding Evox Therapeutics, Vaccitech, and Lab282.

We use cookies to give you the best experience of using this website. By continuing to use this site, you accept our use of cookies. Please read our Cookie Policy for more information.